Register Financial Advisors LLC Sells 1,918 Shares of Bristol-Myers Squibb (NYSE:BMY)

Register Financial Advisors LLC reduced its stake in Bristol-Myers Squibb (NYSE:BMY) by 40.1% during the second quarter, HoldingsChannel.com reports. The firm owned 2,870 shares of the biopharmaceutical company’s stock after selling 1,918 shares during the quarter. Register Financial Advisors LLC’s holdings in Bristol-Myers Squibb were worth $119,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Strategic Blueprint LLC raised its holdings in Bristol-Myers Squibb by 78.6% in the 4th quarter. Strategic Blueprint LLC now owns 9,715 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 4,275 shares during the last quarter. RFG Advisory LLC raised its holdings in Bristol-Myers Squibb by 6.3% in the 4th quarter. RFG Advisory LLC now owns 18,016 shares of the biopharmaceutical company’s stock worth $924,000 after acquiring an additional 1,064 shares during the last quarter. Turtle Creek Wealth Advisors LLC purchased a new position in Bristol-Myers Squibb in the 4th quarter worth approximately $40,000. PBMares Wealth Management LLC raised its holdings in Bristol-Myers Squibb by 6.2% in the 4th quarter. PBMares Wealth Management LLC now owns 4,141 shares of the biopharmaceutical company’s stock worth $212,000 after acquiring an additional 242 shares during the last quarter. Finally, Sequoia Financial Advisors LLC raised its holdings in Bristol-Myers Squibb by 121.7% in the 4th quarter. Sequoia Financial Advisors LLC now owns 77,049 shares of the biopharmaceutical company’s stock worth $3,953,000 after acquiring an additional 42,301 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Price Performance

Shares of BMY traded down $0.13 during midday trading on Friday, hitting $46.72. 14,083,504 shares of the company traded hands, compared to its average volume of 15,967,806. The firm has a 50 day moving average of $43.02 and a 200-day moving average of $46.65. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $63.41. The stock has a market cap of $94.71 billion, a price-to-earnings ratio of -15.07, a PEG ratio of 12.51 and a beta of 0.44. The company has a debt-to-equity ratio of 2.86, a quick ratio of 0.99 and a current ratio of 1.16.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating the consensus estimate of $1.64 by $0.43. Bristol-Myers Squibb had a negative net margin of 14.06% and a positive return on equity of 12.51%. The business had revenue of $12.20 billion during the quarter, compared to the consensus estimate of $11.54 billion. During the same quarter in the prior year, the firm earned $1.75 EPS. The business’s revenue was up 8.7% on a year-over-year basis. On average, analysts forecast that Bristol-Myers Squibb will post 0.77 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, August 1st. Stockholders of record on Friday, July 5th were given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 5.14%. The ex-dividend date was Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is -77.42%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BMY. Wells Fargo & Company boosted their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. BMO Capital Markets decreased their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research note on Friday, April 26th. StockNews.com raised shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. Cantor Fitzgerald reissued a “neutral” rating and set a $45.00 price objective on shares of Bristol-Myers Squibb in a research report on Monday, July 22nd. Finally, Barclays downgraded shares of Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and set a $41.00 price objective for the company. in a research report on Monday, July 29th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $55.79.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.